CLL Global Research Foundation

RESEARCH GRANTS: The CLL Global Research Foundation's primary activity is to accelerate research. The need is urgent to accelerate promising, untapped areas of research. CLL Global provides grants through several mechanisms to fund novel, patient-oriented concepts. The intention is to fund the best CLL science in the world. In particular, CLL Global targets monoclonal antibodies, prognostic factors, vaccines & gene therapy, CLL survival pathway, genetics, molecular targets, and drug development. Continued on Schedule O A Scientific Advisory Board (SAB) develops the research priorities and oversees the development and implementation of the submission, evaluation and funding process for grant application cycles. SAB members have extensive experience in treating CLL patients, developing new drugs and other tools, and studying various aspects of the disease. The research grant section also allows support of postdoctoral fellows conducting a CLL-specific project. In 2023, CLL Global awarded new research/individual grants ranging from $100,000-$250,000. Applicants initially submit proposals for up to $110,000 in funding for one year. Applicants identify project milestones. Upon demonstration of sufficient progress, investigators will be considered for a second year of funding. For accounting purposes, CLL Global expenses grants at the time of completion of a sponsored research agreement.

EDUCATION: CLL Global Research Foundation hosts annual interactive patient education events where CLL patients learn about emerging therapies, current treatment options and support resources from leading CLL experts. Both virtual and in-person events were held in 2023.

ALLIANCE: The US/European Alliance for the Therapy of CLL (Alliance) is comprised of 25 individuals from the United States and Europe, representing the world's experts in CLL research. The members are divided into working groups focusing on one of five big ideas in CLL research (new drugs, gene/vaccine therapy, genetics, CLL-stromal interactions, transplant/immune reconstitution). The Alliance was built to encourage close collaboration within and among working groups. As such, meetings are held to bring investigators together to collaborate.